SS-31 (Elamipretide) · Research brief
SS-31 Elamipretide In Vitro Study: Cell Model Findings
Short answer
An SS-31 elamipretide in vitro study generally falls into one of three model families: cell-free preparations such as isolated mitochondria and synthetic lipid bilayers, permeabilized tissue preparations such as saponin-treated muscle fibers, and intact cultured cells including cardiomyocytes, renal tubular epithelial cells and neuronal lines.
An SS-31 elamipretide in vitro study generally falls into one of three model families: cell-free preparations such as isolated mitochondria and synthetic lipid bilayers, permeabilized tissue preparations such as saponin-treated muscle fibers, and intact cultured cells including cardiomyocytes, renal tubular epithelial cells and neuronal lines. Across these systems the published record describes an aromatic-cationic tetrapeptide that accumulates in the inner mitochondrial membrane, associates with the phospholipid cardiolipin, and is reported to influence electron transport efficiency, mitochondrial reactive oxygen species signals, membrane potential and ATP-linked respiration. The in vitro literature is mechanistic rather than outcome-based: it describes what the molecule appears to do to a membrane and to an electron transport chain, not what happens in an organism. Real Peptides supplies SS-31 as a research-use-only catalog compound and publishes independent third-party certificates of analysis for every batch at /coas/.
What is SS-31 and why is it studied in cell-free and cell-based systems?
SS-31 is a synthetic tetrapeptide, also referred to in the literature as elamipretide, MTP-131 and by the research code Bendavia, built from an alternating aromatic-cationic motif. The sequence described in the published chemistry is D-Arg-Dmt-Lys-Phe-NH2, with a dimethyltyrosine residue and a free amide at the C-terminus. The alternating pattern of basic and aromatic residues is the structural feature that the mechanistic literature returns to repeatedly, because it gives the molecule a net positive charge along with aromatic surfaces that can insert into a lipid environment.
In vitro systems are used because they strip away the variables that make whole-animal work difficult to interpret. In an isolated mitochondria preparation, a researcher controls the substrate supplied to the respiratory chain, the oxygen tension, the calcium load, the ADP availability and the exact concentration of peptide in the buffer. Reactive oxygen species probes can be added directly. Respiration can be measured continuously. None of that is possible in a living animal, where distribution, clearance and compensatory signaling all intervene.
The second reason is targeting. Many mitochondria-directed compounds rely on a triphenylphosphonium cation or a similar delocalized lipophilic cation to accumulate in the matrix in proportion to membrane potential. The literature on this peptide describes a different behavior: research reports that its association with the inner membrane does not depend on membrane potential in the same way, which matters in exactly the models where potential has collapsed, such as ischemic or depolarized preparations. Cell-free assays are the cleanest place to test that claim, because potential can be clamped, dissipated with an uncoupler, or manipulated with inhibitors while the readout stays quantitative.
Third, in vitro work allows separation of direct chemical antioxidant behavior from structural effects on the membrane. That distinction has been central to how the mechanism was revised over time, and it is discussed in its own section below. For researchers surveying the compound class, the SS-31 compound overview collects the broader context around this peptide.
How does SS-31 interact with cardiolipin in isolated mitochondria?
The cardiolipin interaction is the organizing hypothesis of the modern in vitro literature. Cardiolipin is a four-tailed, dimeric phospholipid essentially confined to the inner mitochondrial membrane, where it is enriched in the cristae, stabilizes respiratory supercomplexes, and anchors cytochrome c to the membrane surface. Because cardiolipin carries negative charge, a cationic peptide with aromatic residues is chemically well suited to associate with it through a combination of electrostatic attraction and hydrophobic insertion.
The paper The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin, published in the Journal of the American Society of Nephrology in 2013, is the study most often cited for this mechanism. It reports that the peptide associates with cardiolipin and, in ischemic mitochondrial preparations, is linked to restored electron transport. The companion report Targeting mitochondrial cardiolipin and the cytochrome c/cardiolipin complex to promote electron transport and optimize mitochondrial ATP synthesis, in the British Journal of Pharmacology in 2014, frames the same interaction in terms of the cytochrome c and cardiolipin complex and its peroxidase activity, which is the chemical step that converts cytochrome c from an electron carrier into a lipid-oxidizing enzyme under stress.
The mechanistic logic the literature describes runs as follows. When cardiolipin is oxidized or when cytochrome c binds it too tightly, electron flow between complex III and complex IV is impaired and cytochrome c gains peroxidase behavior, oxidizing cardiolipin further and promoting its own release. A molecule that selectively occupies cardiolipin surfaces could, in principle, limit that peroxidase conversion and keep cytochrome c in its electron-carrying role. Studies report findings consistent with that model, although the quantitative contribution of each step remains a subject of ongoing work.
The review First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics, also in the British Journal of Pharmacology in 2014, gathers this reasoning into a single framework. Readers should note that it is a review rather than a primary data report, so it is best used for context rather than as evidence of any specific assay result.
What do isolated mitochondria assays report about oxygen consumption and ATP synthesis?
Isolated mitochondria work is the bedrock of the in vitro record, and the endpoints are standard respirometry measures: state 2 respiration on substrate alone, state 3 respiration with saturating ADP, state 4 or leak respiration after ADP depletion or with ATP synthase inhibited, the respiratory control ratio, and ATP production measured with luciferase or coupled enzyme assays.
Studies report that in mitochondria isolated from ischemic or otherwise stressed tissue, exposure to the peptide in the respiration buffer is associated with improved coupling, meaning more oxygen consumed in the ADP-stimulated state relative to the leak state. The 2013 Journal of the American Society of Nephrology report cited above is the clearest example in the renal field, and it ties the respiratory improvement to the cardiolipin interaction rather than to a free radical scavenging effect.
The earlier work Mitochondria-targeted peptide accelerates ATP recovery and reduces ischemic kidney injury, published in the Journal of the American Society of Nephrology in 2011, centers on ATP recovery as the primary bioenergetic endpoint. Its design combines tissue-level and mitochondrial measurements, which makes it a bridge study between the cell-free and whole-organ literature rather than a pure in vitro paper.
Two caveats apply to all of this. First, isolated mitochondria are a damaged preparation by definition: the isolation procedure shears the organelle network, strips contact sites with the endoplasmic reticulum, and selects for the subpopulation that survives differential centrifugation. A compound that stabilizes membranes may therefore look more effective in a preparation that has already been mechanically stressed than it would in an intact cell. Second, respirometry outcomes are sensitive to the substrate chosen, to the calcium content of the buffer, and to the protein concentration used. Comparisons between laboratories are only meaningful when those parameters match, and the published literature is not uniform on them.
For these reasons, well-designed contemporary work pairs isolated-organelle respirometry with intact-cell extracellular flux measurements, so that basal respiration, ATP-linked respiration, proton leak, maximal respiration after uncoupling and non-mitochondrial oxygen consumption can be resolved in a cell that still has its cytoskeleton and its organelle contacts intact.
What do reactive oxygen species assays show in cell models of SS-31?
Reactive oxygen species endpoints appear in nearly every in vitro report on this peptide, and the interpretation of those endpoints has changed over two decades of work. The earliest publication in the series, Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury, appeared in the Journal of Biological Chemistry in 2004 and framed the molecules explicitly as targeted antioxidants, reporting reduced mitochondrial swelling and reduced oxidative cell death in the models tested.
The later mechanistic literature complicates that framing. The dimethyltyrosine residue does have intrinsic radical-scavenging chemistry, but the concentrations at which activity is described in mitochondrial preparations are generally far below what stoichiometric scavenging of a continuous radical flux would require. The reinterpretation offered in the 2014 British Journal of Pharmacology papers is that lowered reactive oxygen species signals are largely a downstream consequence of improved electron transport and reduced electron leak, not of direct quenching. In other words, the peptide may reduce the production of superoxide at the source rather than mopping it up after the fact.
The practical assay toolkit is familiar: MitoSOX or related mitochondria-localized superoxide indicators, dichlorofluorescein derivatives for general cellular oxidant load, Amplex Red for extramitochondrial hydrogen peroxide release, aconitase activity as an indirect superoxide marker, and lipid peroxidation markers such as malondialdehyde or 4-hydroxynonenal adducts. Oxidized cardiolipin species can be resolved by mass spectrometry, which is the most direct readout given the proposed mechanism.
Each probe carries interpretive baggage. Dichlorofluorescein is not specific for any single oxidant and is sensitive to intracellular esterase activity and to peroxidase contamination. MitoSOX fluorescence depends on membrane potential for accumulation, so any compound that alters potential alters probe loading, which is a direct confound in this exact context. Research suggests that the most defensible designs pair at least two orthogonal readouts and include a potential-independent control. Reports that rely on a single fluorescent probe without potential correction should be read with that limitation in mind.
What has cardiomyocyte research reported about this peptide?
Cardiac models are heavily represented because the heart has among the highest mitochondrial volume density of any tissue and because cardiolipin remodeling has a well-described role in cardiac bioenergetics. In vitro cardiac work uses several preparations: neonatal rat ventricular myocytes, adult mouse or rat cardiomyocytes isolated by enzymatic digestion, the H9c2 rat cardiomyoblast line as a convenience model, and increasingly human induced pluripotent stem cell derived cardiomyocytes.
The endpoints in these systems extend beyond respirometry. Researchers measure sarcomere shortening and relaxation kinetics, calcium transient amplitude and decay, mitochondrial membrane potential with TMRM or JC-1, permeability transition pore opening with calcein-cobalt quenching, and cell viability after simulated ischemia and reoxygenation, which is produced by switching to a glucose-free, hypoxic buffer and then restoring normal conditions.
The cardiac literature on this peptide includes Mitochondrial targeted antioxidant peptide ameliorates hypertensive cardiomyopathy, published in the Journal of the American College of Cardiology in 2011. That report is a whole-animal study with supporting mitochondrial and tissue-level analysis rather than a pure cell culture study, and it should be cited as such. Its value for the in vitro reader is that it links mitochondrial endpoints measured ex vivo to structural and functional cardiac measures in the same model, which is the kind of connection that cell work alone cannot supply.
The principal limits in cardiomyocyte models are developmental and metabolic. Neonatal myocytes and the H9c2 line are glycolytically biased and do not reproduce adult oxidative metabolism, so a compound acting on oxidative phosphorylation may show a muted effect. Stem cell derived cardiomyocytes are immature by default and often require metabolic maturation protocols, fatty acid containing media or extended culture, before oxidative endpoints become informative. Adult isolated myocytes are the most physiologically relevant but survive only hours in culture, which caps the observation window. Any in vitro cardiac finding should be read against the specific preparation used.
What do renal cell and kidney tissue models report?
The kidney is the other major organ system in this literature, and for a structural reason: the proximal tubule is densely packed with mitochondria to power sodium reabsorption and relies almost entirely on oxidative metabolism, which makes it unusually vulnerable to ischemic energy failure. Renal in vitro work typically uses primary proximal tubular epithelial cells, immortalized lines such as HK-2 or LLC-PK1, freshly isolated tubule suspensions, or mitochondria isolated directly from cortical tissue.
The two Journal of the American Society of Nephrology papers cited above anchor this section. The 2011 report centers on ATP recovery after ischemia and associated kidney injury measures, and the 2013 report provides the cardiolipin-based mechanism along with mitochondrial functional data in ischemic preparations. Together they describe a model in which early mitochondrial failure, rather than later inflammatory injury, is the point of intervention, and in which protecting the inner membrane lipid environment is proposed as the mechanism of that early effect.
In cultured renal cells, the usual injury models are hypoxia and reoxygenation, ATP depletion with antimycin A or similar inhibitors followed by recovery, cisplatin or other mitochondrial toxicants, and high-glucose conditions for diabetic injury modeling. Endpoints include ATP content, membrane potential, mitochondrial morphology by confocal imaging of the network, release of cytochrome c into the cytosolic fraction, caspase activation and loss of epithelial polarity or tight junction integrity measured by transepithelial resistance.
The limits here are notable. HK-2 and LLC-PK1 cells are transformed and metabolically shifted toward glycolysis, so they tolerate mitochondrial inhibition far better than a real proximal tubule would, which can both mask protective effects and exaggerate viability readouts. Primary tubular cells dedifferentiate quickly in culture and lose their characteristic transporter expression. Tubule suspensions preserve more of the native phenotype but are short-lived. Studies report findings consistent across several of these preparations, which strengthens the picture, but no single renal cell model reproduces the energetic demand of the intact nephron.
How do neuronal, muscle and other cell models fit into the picture?
Beyond heart and kidney, the in vitro record extends into skeletal muscle, neurons, endothelium, retina, liver and immune cells, because mitochondrial dysfunction is a shared feature across those tissues. The methods differ, but the endpoint grammar is the same: respiration, ATP, membrane potential, reactive oxygen species, network morphology and viability under a defined stressor.
Skeletal muscle work often uses permeabilized fiber bundles rather than isolated mitochondria. Saponin selectively permeabilizes the sarcolemma while leaving mitochondrial membranes and the organelle network intact in situ, which preserves the architecture that isolation destroys. Mitochondrial-targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice, published in Aging Cell in 2013, combines ex vivo muscle measurements with in vivo performance endpoints in an aging model, and it is frequently cited as evidence that mitochondrial endpoints and functional endpoints can move together in the same preparation. It is an animal study with ex vivo mechanistic measures, not a culture study, and should be described that way.
Neuronal models usually employ primary hippocampal or cortical cultures, SH-SY5Y cells, or induced neurons, with stressors such as glutamate excitotoxicity, amyloid-beta exposure, rotenone or MPP+ complex I inhibition, or oxygen-glucose deprivation. Because neurons depend on mitochondrial trafficking along axons, live imaging of mitochondrial motility and fission-fusion dynamics becomes a meaningful additional endpoint in these systems.
Endothelial and retinal models add barrier integrity and angiogenic readouts. Immune cell work introduces an important caveat specific to cationic peptides: molecules with a strong positive charge can interact with plasma membranes and with bacterial-type membranes, so cytotoxicity and off-target membrane effects must be excluded with appropriate controls rather than assumed absent.
The breadth of models is a strength of this literature, since a mechanism that depends on an inner membrane phospholipid should generalize across tissues. It is also a weakness when individual reports use short exposure windows, single concentrations or single endpoints, which is common in exploratory cell work.
What do proteomic and biophysical binding studies add to the mechanism?
Two more recent strands of work attempt to resolve what the molecule physically does at the membrane, which is where the older antioxidant framing was weakest.
The first is chemical crosslinking mass spectrometry. Mitochondrial protein interaction landscape of SS-31, published in the Proceedings of the National Academy of Sciences in 2020, maps the protein neighborhood the peptide occupies within mitochondria, moving the discussion from a single lipid interaction to a broader set of protein and lipid contacts in the inner membrane environment. Work of this kind is valuable because it is unbiased: rather than testing a hypothesis about one target, it reports what the compound is near.
The second is membrane biophysics. The mitochondria-targeted peptide SS-31 binds lipid bilayers and modulates surface electrostatics as a key component of its mechanism of action, published in the Journal of Biological Chemistry in 2020, examines binding to defined lipid bilayers and proposes that modulation of membrane surface charge is a central part of the mechanism rather than an incidental property. Surface electrostatics matter because the local charge environment of the inner membrane influences how peripheral proteins such as cytochrome c dock, how protons travel along the membrane surface toward ATP synthase, and how tightly supercomplexes pack.
These studies use model systems that are even further removed from physiology than cell culture: liposomes, nanodiscs, supported bilayers and purified protein preparations. That distance is the point. They allow a mechanism to be tested without cellular compensation, and they generate predictions that can then be checked in mitochondria and in cells. They cannot, on their own, establish that the same interaction dominates in a living cell, where the membrane contains hundreds of lipid species, a crowded protein landscape and an active remodeling machinery.
Taken together with the cardiolipin work, the biophysical and proteomic reports describe a compound whose primary action is best modeled as a membrane-level effect with downstream bioenergetic consequences, rather than as classical antioxidant chemistry.
Which assay endpoints appear most often in cell-model work on this peptide?
A researcher planning a literature-aligned experiment will encounter a consistent core set of endpoints, and knowing the set makes comparison across papers much easier.
Bioenergetic endpoints
Oxygen consumption rate by extracellular flux analysis in intact cells, or by Clark electrode and high-resolution respirometry in isolated mitochondria and permeabilized fibers. Derived parameters include basal respiration, ATP-linked respiration, proton leak, maximal respiration after chemical uncoupling, spare respiratory capacity and the respiratory control ratio. ATP content measured by luciferase assay, and in some designs the ATP to ADP ratio or the phosphocreatine pool.
Membrane and structural endpoints
Mitochondrial membrane potential by TMRM, TMRE or JC-1, read either as whole-well fluorescence or by confocal imaging with potential-independent controls. Cristae architecture by transmission electron microscopy, which is slow and labor-intensive but is the only direct structural readout of the inner membrane. Network morphology by live imaging with mitochondria-targeted fluorescent proteins, scored for fragmentation, elongation and branching. Permeability transition pore opening by calcein-cobalt quenching or by calcium retention capacity in isolated organelles.
Oxidative and lipid endpoints
Mitochondria-localized superoxide probes, hydrogen peroxide efflux assays, aconitase activity, glutathione redox ratio, lipid peroxidation markers and, in the most mechanism-specific designs, mass spectrometry of cardiolipin species including oxidized and remodeled forms.
Downstream cellular endpoints
Viability and death pathway markers, cytochrome c distribution between mitochondrial and cytosolic fractions, caspase activity, and tissue-specific functional measures such as contractility in cardiomyocytes or barrier resistance in epithelial monolayers.
Research suggests the most informative published designs include a stressor, a vehicle control, at least two mechanistically independent endpoints, and a concentration series rather than a single point. Where a report presents only one endpoint at one concentration, the finding is hypothesis-generating and should be described that way.
What concentration framework applies to laboratory work with this compound?
Real Peptides does not provide preparation, handling or use guidance, because these are research-use-only compounds supplied for laboratory investigation.
The relevant arithmetic is concentration math.
The published isolated-mitochondria literature generally describes activity at low concentrations, with reports spanning nanomolar to low micromolar ranges depending on the preparation and the endpoint. Intact-cell work typically uses higher medium concentrations than cell-free work, because the compound must cross the plasma membrane and partition into the inner mitochondrial membrane, and because serum proteins in the medium bind a fraction of any peptide added.
Several variables shift effective concentration independently of what was weighed out. Serum content in the medium changes free peptide availability. Adsorption to plasticware is a real loss pathway for small cationic peptides, particularly at low concentrations in low-protein buffers. Peptide content in a lyophilized powder is not identical to gross mass because of counterion and residual solvent content, which is why net peptide content, where reported on a certificate of analysis, is the figure used for molar calculations. Freeze-thaw cycling and storage temperature affect stability over time.
These are measurement considerations, not instructions. Any specific laboratory protocol is the responsibility of the investigating laboratory and its institutional oversight.
What are the main limits of in vitro findings on this peptide?
The honest summary is that the cell-model literature establishes plausibility and mechanism, not efficacy. Several specific limits deserve attention.
Model artifact is the first. Isolated mitochondria are mechanically injured and selected by the isolation procedure. Immortalized cell lines are metabolically rewired toward glycolysis, which systematically blunts the apparent importance of oxidative phosphorylation. Standard culture medium contains supraphysiological glucose and is typically equilibrated at atmospheric oxygen, roughly four to ten times the oxygen tension of most tissues, which chronically elevates baseline oxidative stress and can make an oxidant-related intervention look more consequential than it would at physiological oxygen.
Probe confounds are the second. As noted above, the most common mitochondrial reactive oxygen species indicators accumulate in a potential-dependent manner, so changes in potential and changes in oxidant production are entangled in the raw signal unless the design controls for it explicitly.
The third limit is publication structure. A large part of this literature was generated by a small number of closely connected groups and is reviewed by overlapping authorship, which is common for a compound class with a single originating chemistry but means that independent replication carries extra weight. Where independent laboratories using different models converge on similar endpoints, confidence increases.
Fourth, acute exposure windows dominate. Many cell experiments run for minutes to hours. Mitochondrial biogenesis, mitophagy and cardiolipin remodeling operate on longer timescales, so short assays cannot capture adaptive responses, and long culture introduces its own confounds.
Fifth, concentration translation is unreliable. A concentration that produces an effect in a buffer containing no serum protein cannot be mapped onto a tissue concentration in an organism, where distribution, binding and clearance all intervene. In vitro potency should be treated as a property of the assay, not as a property of the compound in a body.
Finally, none of this literature supports any claim about outcomes in humans. The compound is a research chemical in this context, and cell-model findings are the beginning of an evidence chain, not its end.
How do cell-model findings compare with animal and clinical-program work?
Separating the assay literature from the organism literature is useful because the two answer different questions, and a searcher looking for assay-level evidence is usually not looking for whole-animal outcomes.
Animal studies in this field typically measure organ-level function, histology, survival and ex vivo mitochondrial parameters harvested after the experiment. The Aging Cell 2013 skeletal muscle report and the Journal of the American College of Cardiology 2011 hypertensive cardiomyopathy report are examples of designs that pair mitochondrial measurements with functional outcomes in the same animals. Those designs add information that cell work cannot provide, including whether a compound reaches the target tissue at all and whether mitochondrial changes track with physiological performance.
Human clinical programs for this molecule have been conducted in mitochondrial and ophthalmic indications. Those programs are governed by regulatory frameworks and their results sit outside the scope of a cell-model review. Where this page references trial-stage work, it does so only to note the existence of the clinical program and the separation between assay evidence and clinical evidence; no outcome is claimed here, and any specific trial result should be read in its own published report.
The translational gap between tiers is wide for a peptide of this type. Cell-free data establish that a molecule can interact with a lipid and alter electron transport in a controlled buffer. Cell data establish that the interaction survives the plasma membrane barrier and produces a measurable change in an intact cell. Animal data establish tissue exposure and whole-organ consequence. Clinical programs establish, or fail to establish, human relevance. Findings at any tier constrain but do not guarantee the tier above it.
For researchers designing new work, the practical implication is that in vitro findings are best used to generate specific, falsifiable predictions about mechanism, such as a predicted change in cardiolipin oxidation species or in supercomplex assembly, rather than as a basis for predicting outcomes in a more complex system.
How can a laboratory verify material identity before procurement?
Material quality is a direct determinant of whether an in vitro result is reproducible, because a peptide assay is only as reliable as the identity and consistency of what was weighed into the buffer. Several verification steps apply to any research peptide.
The first is molecular identity. A laboratory should confirm the sequence and the molecular weight expected for the compound and check the CAS number and molecular formula listed by the supplier against independent chemical databases before procurement. For a tetrapeptide, mass spectrometric confirmation of the expected mass is a straightforward identity check, and the analytical documentation supplied with a lot should show it.
The second is batch-level documentation. Real Peptides publishes independent third-party certificates of analysis for every batch, and those documents are publicly accessible at /coas/ rather than furnished on request only. A certificate tied to a specific lot number, rather than a generic document, is what allows a laboratory to connect the material in a vial to the analytical data describing it, which matters when an experiment is repeated months later with a different lot.
The third is net peptide content and counterion information, which affect molar calculations as described above. A gross mass is not a molar quantity until peptide content is known.
The fourth is record keeping. Reproducible cell work requires that the lot number, the certificate reference, the storage history and the preparation date be recorded alongside the experimental data, so that an anomalous result can be traced to material rather than to method.
Real Peptides supplies SS-31 as a research-use-only catalog compound, with background on the molecule collected on the SS-31 overview page. The full research catalog is listed at /shop/, and company location details are available at /location/. No preparation, handling or use guidance is provided with any catalog compound, because these materials are supplied strictly for laboratory research.
All compounds discussed on this page are sold for laboratory research use only and are not for human consumption.
References
- Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury. Journal of Biological Chemistry. 2004. PMID: 15178689
- Mitochondria-targeted peptide accelerates ATP recovery and reduces ischemic kidney injury. Journal of the American Society of Nephrology. 2011. PMID: 21546574
- Mitochondrial targeted antioxidant peptide ameliorates hypertensive cardiomyopathy. Journal of the American College of Cardiology. 2011. PMID: 21620606
- Mitochondrial-targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice. Aging Cell. 2013. PMID: 23692570
- The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. Journal of the American Society of Nephrology. 2013. PMID: 23813215
- Targeting mitochondrial cardiolipin and the cytochrome c/cardiolipin complex to promote electron transport and optimize mitochondrial ATP synthesis. British Journal of Pharmacology. 2014. PMID: 24134698
- First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. British Journal of Pharmacology. 2014. PMID: 24117165
- The mitochondria-targeted peptide SS-31 binds lipid bilayers and modulates surface electrostatics as a key component of its mechanism of action. Journal of Biological Chemistry. 2020. PMID: 32273339
- Mitochondrial protein interaction landscape of SS-31. Proceedings of the National Academy of Sciences. 2020. PMID: 32554501
Build a pack
Researching more than one compound?
Build a multi-vial pack and the discount applies automatically as you add vials.
Questions
RESEARCH USE ONLY · NOT EVALUATED BY THE FDA